Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: A systematic review

Current Oncology

Volumn 22, Issue 3, 2015, Pages e183-e215

  Ellis, P M ^a,b   Coakley, Nadia ^a,c   Feld, R ^d   Kuruvilla, S ^e   Ung, Y C ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Department of Oncology ^*  (Canada)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

EGFR inhibitors; Mutation status; Non small small cell lung cancer; Systematic review

Indexed keywords

AFATINIB; BEVACIZUMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; ICOTINIB; PACLITAXEL; PEMETREXED; SORAFENIB;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; DECISION MAKING; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84931374307     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2566     Document Type: Article

References (109)

1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
2. Schiller JH, Harrington D, Belani CP, et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–97.
4. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354–62. [Erratum in: J Clin Oncol 2004;22:209]
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103.
6. Feld R, Sridhar SS, Shepherd FA, et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol 2006;1:367–76.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
8. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379–91.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
11. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.
12. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34. [Erratum in: Stat Med 2004;23:1817]
13. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the torch randomized trial. J Clin Oncol 2012;30:3002–11.
14. Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (invite): a randomized, phase ii study. J Clin Oncol 2008;26:4253–60.
15. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase ii trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863–9.
16. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (cbdca) plus paclitaxel (txl) in non-small cell lung cancer (nsclc) patients (pts) with EGFR mutations: a phase iii study by North East Japan Gefitinib Study Group [abstract 8016]. J Clin Oncol 2009;27:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8016; cited 29 March 2015]
17. Agarwal S, Hirsh V, Agulnik JS, Cohen V, Mihalcioiu CL, Whittom R. A phase ii study of gefitinib (g) versus carboplatin and gemcitabine (cg) in chemotherapy-naive patients with advanced non-small cell lung cancer (nsclc) and ecog performance status (ps) 2 [abstract e18090]. J Clin Oncol 2010;28:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e18090; cited 29 March 2015]
18. Morere JF, Brechot JM, Westeel V, et al. Randomized phase ii trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (ifct-0301 study). Lung Cancer 2010;70:301–7.
19. Reck M, Von Pawel J, Fischer JR, et al. Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung cancer (nsclc): a randomized phase ii study of the German Thoracic Oncology Working Group [abstract 7565]. J Clin Oncol 2010;28:15s. [Available online at: http://meetinglibrary.asco.org/content/44017–74;cited 29 March 2015]
20. LeCaer H, Barlesi F, Corre R, et al. on behalf of the gfpc 0504 team. A multicentre phase ii randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs. the reverse sequence, in elderly patients with advanced non small–cell lung cancer selected with a comprehensive geriatric assessment (the gfpc 0504 study). Br J Cancer 2011;105:1123–30.
21. Chen YM, Tsai CM, Fan WC, et al. Phase ii randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012;7:412–18.
22. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase iii trial—intact 1. J Clin Oncol 2004;22:777–84.
23. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase iii trial—intact 2. J Clin Oncol 2004;22:785–94.
24. Herbst RS, Prager D, Hermann R, et al. on behalf of the tribute investigator group. tribute: a phase iii trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892–9.
25. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545–52.
26. Nokihara H, Ohe Y, Yamada K, et al. Randomized phase ii study of sequential carboplatin/paclitaxel (cp) and gefitinib (g) in chemotherapy-naive patients with advanced nonsmall-cell lung cancer (nsclc): final results [abstract 8069]. J Clin Oncol 2008;26:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8069; cited29 March 2015]
27. Mok TSK, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase ii study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080–7.
28. Riely GJ, Rizvi NA, Kris MG, et al. Randomized phase ii study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:264–70.
29. Mok TS, Wu YL, Thongprasert S, et al. A randomized placebocontrolled phase iii study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (nsclc): fastact-ii [abstract 7519]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/93895-114; cited 5 April 2015]
30. Goss G, Ferry D, Wierzbicki R, et al. Randomized phase ii study of gefitinib compared with placebo in chemotherapynaive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253–60.
31. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase ii study. Ann Oncol 2011;22:1528–34.
32. Stinchcombe TE, Peterman AH, Lee CB, et al. A randomized phase ii trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age >= 70 years) with stage iiib/iv non-small cell lung cancer. J Thorac Oncol 2011;6:1569–77.
33. Thomas M, Reuss A, Fischer JR, et al. Innovations: randomized phase ii trial of erlotinib (e)/bevacizumab (b) compared with cisplatin (p)/gemcitabine (g) plus b in first-line treatment of advanced nonsquamous (ns) non–small cell lung cancer (nsclc) [abstract 7504]. J Clin Oncol 2011;29:. [Available online at: http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/7504; cited 29 March 2015]
34. Boutsikou E, Kontakiotis T, Zarogoulidis P, et al. Docetaxel–carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther 2013;6:125–34.
35. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (topical): a double-blind, placebocontrolled, phase 3 trial. Lancet Oncol 2012;13:1161–70.
36. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
37. Yang CH, Fukuoka M, Mok TS, et al. Final overall survival (os) results from a phase iii, randomised, open-label, firstline study of gefitinib (g) v carboplatin/paclitaxel (c/p) in clinically selected patients with advanced non-small cell lung cancer (nsclc) in Asia (ipass) [abstract LBA2]. Ann Oncol 2010;21(suppl 8):viii1–2.
38. Han JY, Park K, Kim SW, et al. First-signal: first-line singleagent Iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122–8.
39. LeCaer H, Greillier L, Corre R, et al. A multicenter phase ii randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the gfpc 0505 study). Lung Cancer 2012;77:97–103.
40. Janne PA, Wang X, Socinski MA, et al. Randomized phase ii trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: calgb 30406 trial. J Clin Oncol 2012;30:2063–9.
41. Choi YJ, Kim SW, Lee DH, et al. Paclitaxel/carboplatin (pc) intercalated with gefitinib or paclitaxel/carboplatin (pc) for advanced non-small cell lung cancer (nsclc) in selected population who were smoker or wild-type EGFR: randomized phase ii study [abstract e19079]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/116000–132; cited 29 March 2015]
42. Michael M, White S, Abdi E, et al. A multi-center randomized, open-label phase ii trial of Tarceva in sequential combination with gemcitabine compared to gemcitabine monotherapy as first-line therapy in elderly or ecog ps of 2 patients with advanced nsclc. J Thorac Oncol 2012;3:S177–8.
43. Liang J, Ahn M, Kang J, et al. First-line treatment (txt) with pemetrexed–cisplatin (pc), followed sequentially by gefitinib (g) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced nsclc: an open-label, randomized phase ii trial [abstract 7591]. J Clin Oncol 2010;28:. [Available online at: http://meetinglibrary.asco.org/content/31344–74;cited 29 March 2015]
44. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
45. Inoue A, Kobayashi K, Maemondo M, et al. Final overall survival results of NEJ002, a phase iii trial comparing gefitinib to carboplatin (cbdca) plus paclitaxel (txl) as the first-line treatment for advanced non-small cell lung cancer (nsclc) with EGFR mutations [abstract 7519]. J Clin Oncol 2011;29:. [Available online at: http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/7519; cited 30 March 2015]
46. Mitsudomi T, Morita S, Yatabe Y, et al. on behalf of the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
47. Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of wjtog 3405, a randomized phase iii trial comparing gefitinib (g) with cisplatin plus docetaxel (cd) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (egfr) [abstract 7521]. J Clin Oncol 2012;30:. [Avai lable onl ine at: http://meetingl ibrary.asco.org/content/93530–114; cited 30 March 2015]
48. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non-small-cell lung cancer (optimal,ctong-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42.
49. Zhou C, Wu YL, Liu X, et al. Overall survival (os) results from optimal (ctong 0802), a phase iii trial of erlotinib (e) versus carboplatin plus gemcitabine (gc) as first-line treatment for Chinese patients with EGFR mutation–positive advanced non-small cell lung cancer (nsclc) [abstract 7520]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/96275–114; cited 30 March 2015]
50. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive nonsmall- cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
51. Yang JCH, Schuler MH, Yamamoto N, et al. lux-Lung 3: a randomized, open label, phase iii study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR–activating mutations [abstract LBA7500]. J Clin Oncol 2012;30:. [Available online at: http://meeting.ascopubs.org/cgi/content/short/30/18_suppl/LBA7500; cited 29 March 2015]
52. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (lux-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–22.
53. Hirsch FR, Kabbinavar F, Eisen T, et al. A randomized, phase ii, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3567–73.
54. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K on behalf of the sign study group. Phase ii, open-label, randomized study (sign) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stage iiib or iv) non-small-cell lung cancer. Anticancer Drugs 2006;17:401–9.
55. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372:1809–18.
56. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase iii study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244–52.
57. Hong J, Kyung SY, Lee SP, et al. Randomized phase ii study of pemetrexed versus gefitinib for patients with previously treated non-small cell lung cancer [abstract P-036]. J Thorac Oncol 2010;5(suppl 5):S401.
58. Lee DH, Park K, Kim JH, et al. Randomized phase iii trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307–14.
59. Vamvakas L, Agelaki S, Kentepozidis NK, et al. Pemetrexed (mta) compared with erlotinib (erl) in pretreated patients with advanced non-small cell lung cancer (nsclc): results of a randomized phase iii Hellenic Oncology Research Group Trial [abstract 7519]. J Clin Oncol 2010;28:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7519; cited 30 March 2015]
60. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (titan): a randomised multicentre, openlabel, phase 3 study. Lancet Oncol 2012;13:300–8.
61. Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced nonsmall cell lung cancer: a Hellenic Oncology Research Group (horg) randomized phase 3 study. Cancer 2013;119:2754–64.
62. Okano Y, Ando M, Asami K, et al. Randomized phase iii trial of erlotinib (e) versus docetaxel (d) as second- or third-line therapy in patients with advanced non–small cell lung cancer (nsclc) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (delta) [abstract 8006]. J Clin Oncol 2013;31:. [Avai lable onl ine at: http://meetingl ibrary.asco.org/content/112718–132; cited 30 March 2015]
63. Kelly K, Azzoli CG, Zatloukal P, et al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage iiib/iv non-small-cell lung cancer (nsclc) after failure of prior platinum-based therapy. J Thorac Oncol 2012;7:1041–8.
64. Chen YM, Liu JM, Chou TY, Perng RP, Tsai CM, Whang-Peng J. Phase ii randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 2007;109:1821–8.
65. Aparisi F, Garcia Sanchez J, Sanchez-Hernandez A, et al. A multicenter, open, randomized, phase ii study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (nsclc) [abstract e18036]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/84426–102; cited 30 March 2015]
66. Chen YM, Fan WC, Tsai CM, et al. A phase ii randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol 2011;6:1110–16.
67. Aerts JG, Codrington H, Lankheet NA, et al. on behalf of the nvalt study group. A randomized phase ii study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the nvalt-10 study. Ann Oncol 2013;24:2860–5.
68. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase iii interest trial. J Clin Oncol 2010;28:744–52.
69. Aparisi F, Sanchez-Hernandez A, Giner V, et al. Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (nsclc): a phase ii randomized study [abstract e18049]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/96702–114; cited 30 March 2015]
70. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase ii study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small–cell lung cancer. J Clin Oncol 2007;25:4743–50.
71. Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1002–9.
72. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27:2523–9.
73. Schiller JH, Akerley WL, Brugger W, et al. Results from arq 197-209: a global randomized placebo-controlled phase ii clinical trial of erlotinib plus arq 197 versus erlotinib plus placebo in previously treated egfr inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (nsclc) [abstract LBA7501]. J Clin Oncol 2010;28:. [Available online at: http://meetinglibrary.asco.org/content/51587–74; cited 30 March 2015]
74. Han JY, Lee SH, Yoo NJ, et al. A randomized phase ii study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011;17:1553–60.
75. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-smallcell lung cancer after failure of standard first-line chemotherapy (beta): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377:1846–54.
76. Natale RB, Thongprasert S, Greco FA, et al. Phase iii trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059–66.
77. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase ii study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011;29:4574–80.
78. Sequist LV, Von Pawel J, Garmey EG, et al. Randomized phase ii study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307–15.
79. Spigel DR, Burris HA, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase ii trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582–9.
80. Gian V, Rubin MS, Shipley D, et al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced nonsmall cell lung cancer progressing on erlotinib: a randomized phase ii study of the Sarah Cannon Research institute (scri) [abstract 7587]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/100756–114; cited 30 March 2015]
81. Reckamp KL, Koczywas M, Cristea MC, et al. Randomized phase ii trial oferlotinib (e) plus high-dose celecoxib (hd-c) or placebo in advanced non-small cell lung cancer [abstract 7518]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/93734–114; cited 30 March 2015]
82. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase iii trial. J Clin Oncol 2012;30:2070–8.
83. Witta SE, Jotte RM, Konduri K, et al. Randomized phase ii trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30:2248–55.
84. Besse B, Leighl N, Bennouna J, et al. Phase ii study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 2014;25:409–15.
85. Groen HJ, Socinski MA, Grossi F, et al. A randomized, doubleblind, phase ii study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (nsclc). Ann Oncol 2013;24:2382–9.
86. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase ii trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105–14.
87. Von Pawel J, Papai-Szekely Z, Vinolas N, et al. A randomized phase ii study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous nsclc [abstract 7526]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/76036–102; cited 30 March 2015]
88. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.
89. Gaafar RM, Surmont VF, Scagliotti GV, et al. on behalf of the eortc Lung Cancer Group and the Italian Lung Cancer Project. A double-blind, randomised, placebo-controlled phase iii Intergroup study of gefitinib in patients with advanced nsclc, non-progressing after first line platinumbased chemotherapy (eortc 08021/ilcp 01/03). Eur J Cancer 2011;47:2331–40.
90. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 2005;353:133–44. [Erratum in: N Engl J Med 2006;355:1746]
91. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial). J Clin Oncol 2003;21:2237–46. [Erratum in: J Clin Oncol 2004;22:4863].
92. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–58.
93. Ahn J, Kim S, Ahn M, et al. Randomized phase ii study of gefitinib versus erlotinib in patients with advanced non–small cell lung cancer who failed previous chemotherapy [abstract 7551]. J Clin Oncol 2010;28:. [Available online at: http://meetinglibrary.asco.org/content/50243–74; cited 30 March 2015]
94. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase ii study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337–44.
95. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (icogen): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953–61.
96. Ahn M, Sun J, Ahn JS, et al. Randomized phase iii trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinumbased chemotherapy (kcsg-lu08-01) [abstract 76003]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/80152–102; cited 30 March 2015]
97. Lee DH, Lee JS, Kim SW, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non–small cell lung cancer. Eur J Cancer 2013;49:3111–21.
98. Yang J, Cheng Y, Zhao M, et al. A phase ii trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous nsclc patients with wild-type egfr (ctong 0806) [abstract 8042]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/109906–132; cited 30 March 2015]
99. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (lux-Lung 1): a phase 2b/3randomised trial. Lancet Oncol 2012;13:528–38. [Erratum in: Lancet Oncol 2012;13:e186]
100. Garassino MC, Martelli O, Broggini M, et al. on behalf of the tailor trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (tailor): a randomized controlled trial. Lancet Oncol 2013;14:981–8.
101. Gitlitz BJ, Bernstein ED, Keogh GP, et al. Apricot-i: results of a biomarker-based phase ii randomized placebo controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer [abstract 7528]. J Clin Oncol 2012;29:. [Available online at: http://meetinglibrary.asco.org/content/78570–102; cited 30 March 2015]
102. Belani CP, Nemunaitis JJ, Chachoua A, et al. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 2013;14:557–63.
103. Kim ST, Uhm JE, Lee J, et al. Randomized phase ii study of gefitinib versus erlotinib in patients with advanced non–small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012;75:82–8.
104. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. on behalf of the saturn investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521–9.
105. Takeda K, Hida T, Sato T, et al. Randomized phase iii trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (wjtog 0203). J Clin Oncol 2010;28:753–60.
106. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (inform; c-tong 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012;13:466–75.
107. Bylicki O, Ferlay C, Chouaid C, et al. Efficacy of pemetrexed as second-line therapy in advanced nsclc after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in ifct-gfpc 05-02 phase iii study. J Thorac Oncol 2013;8:906–14.
108. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. atlas: randomized, double-blind, placebo-controlled, phase iiib trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013;31:3926–34.
109. Ahn MJ, Yang JCH, Liang J, et al. Randomized phase ii trial of first-line treatment with pemetrexed–cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, neversmoker patients with advanced non-small cell lung cancer. Lung Cancer 2012;77:346–52.